A Phase 3 interventional study of TAK-003 and Placebo in Dengue Fever, sponsored by Takeda. Completed at 14 sites in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-10-20.
Sponsored by Takeda · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Dengue by Takeda — 2 open to participants now, 5 under way, 3 of them phase 3. Dengue · Takeda.
Among the 17 studies in Dengue by Takeda, this one is the 3rd largest by enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2018, is one of 9 in phase 3, and was the 7th registered.
283 studies on the registry are indexed under Dengue; 44 are open to participants now.
Browse Dengue studies →2 of the 17 studies in Dengue by Takeda are open now, in 4 countries. Recruiting first, the newest first:
Takeda · Sites in Colombia, Thailand
Ages 6 mo–20 mo · Healthy volunteers
Takeda · Sites in Indonesia, Malaysia, Thailand
Ages 6–12 · Healthy volunteers
By country, each count listing its studies:
Of the 27 Dengue studies recruiting now, 16 (59%) set no upper age limit and 11 (41%) stop at 75 or younger; 16 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 10
First in 2013; this study’s year is marked. 3 started in 2018.
This study's enrollment of 923 is above the median of 132 across 197 interventional studies indexed under Dengue.
Median enrollment 400 across the 15 interventional studies, 36,000 across the 2 observational. Of the 12 that completed or were terminated, 11 (92%) have results posted.
This tab as a report to print or save as PDF → With an account.
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
2 of the studies in Dengue by Takeda that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06579755Phase 3TakedaA Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to 79 Years) | 2027-04-14 |
| NCT06388785TakedaA Study to Monitor the Adverse Events of QDENGA Vaccine in Participants in Malaysia | 2027-05-08 |
Add all 2 to your calendar (.ics) → With an account.
Among the 17 studies in Dengue by Takeda, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate lot-to-lot consistency in terms of equivalence of the immune responses induced by 3 consecutive TDV lots in healthy participants aged 18 to 60 years in non-endemic country(ies) for dengue.
The vaccine tested in this study is Takeda's Tetravalent Dengue Vaccine Candidate (TDV). The primary objective of this trial is to investigate lot-to-lot consistency in terms of equivalence of the immune responses induced by 3 consecutive lots of TDV in healthy participants in non-endemic country(ies) for dengue.
The study will enroll approximately 924 healthy participants. Participants will be randomized in 2:2:2:1 to one of 4 trial groups to receive TDV (Lots 1, 2 or 3) or placebo:
In each trial group, all participants will receive 2 doses of TDV or placebo by subcutaneous injection on Days 1 (Month 0) and 90 (Month 3). Immunogenicity will be assessed in participants included in the immunogenicity subset (TDV groups: 176 participants each and placebo group: 88 participants) and safety will be assessed in all participants in each group.
This multi-center trial will be conducted in the United States. The overall time to participate in this study is 270 days. Participants will make multiple visits to the clinic including a final visit at Day 270.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Known or suspected impairment/alteration of immune function, including:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TDV placebo matching injection, subcutaneously (SC) once on Day 1, and Day 90.
Biological: Placebo
Participants were administered TDV lot 1, 0.5 ml (each TDV 0.5 mL dose contained TDV-1, TDV-2, TDV-3, and TDV-4), SC injection, once on Day 1, and Day 90.
Biological: TAK-003
Participants were administered TDV lot 2, 0.5 ml (each TDV 0.5 mL dose contained TDV-1, TDV-2, TDV-3, and TDV-4), SC injection, once on Day 1, and Day 90.
Biological: TAK-003
Participants were administered TDV lot 3, 0.5 ml (each TDV 0.5 mL dose contained TDV-1, TDV-2, TDV-3, and TDV-4), SC injection once on Day 1, and Day 90.
Biological: TAK-003
TDV subcutaneous injection
Also known as: TDV
TDV Placebo-matching normal saline (0.9% NaCl) subcutaneous injection
Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Day 120 in the Immunogenicity Subset
GMTs of neutralizing antibodies for each of the 4 Dengue Serotypes was measured by microneutralization test 50% \[MNT50\]. The 4 dengue virus serotypes were DENV-1, DENV-2, DENV-3 and DENV-4.
Time frame: 1 month post second dose (Day 120)
Percentage of Participants Who Are Seropositive for Each of the 4 Dengue Serotypes at Days 120 and 270 in the Immunogenicity Subset
Seropositivity was defined as a reciprocal neutralizing titer ≥ 10. The 4 dengue virus serotypes were DENV-1, DENV-2, DENV-3 and DENV-4.
Time frame: 1 month post second dose (Day 120) and 6 months post second dose (Day 270)
GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Day 270 in the Immunogenicity Subset
GMTs of neutralizing antibodies for each of the 4 Dengue Serotypes was measured by microneutralization test 50% \[MNT50\]. The 4 dengue virus serotypes were DENV-1, DENV-2, DENV-3 and DENV-4.
Time frame: 6 months post second dose (Day 270)
Percentage of Participants With Solicited Local (Injection Site) Adverse Events (AEs) by Severity After Each Vaccination
Solicited local AEs (at injection site) were collected by participants using diary cards within 7 days after vaccination and included pain (none, mild: no interference with daily activity, moderate: interference with daily activity with or without treatment and severe: prevents daily activity with or without treatment), redness (erythema) (\<25 mm, mild: \>25 - ≤50 mm, moderate: \>50 - ≤100 mm, severe: \>100 mm) and swelling (edema/induration) (\<25 mm, mild: \>25 - ≤50 mm, moderate: \>50 - ≤100 mm, severe: \>100 mm ). The percentages were rounded off to the first decimal place.
Time frame: Within 7 Days of each Vaccination (day of vaccination + 6 days)
Percentage of Participants With Solicited Systemic Adverse Events (AEs) by Severity After Each Vaccination
Solicited systemic AEs include fever, headache, asthenia, malaise and myalgia that occurred within 14 days after each vaccination. Solicited systemic AEs (headache, asthenia, malaise and myalgia) was graded from 0 to 3 by severity; where 0=None, 1=Mild: No interference with daily activity, 2=Moderate: Interference with daily activity, 3=Severe: Prevents daily activity; A systemic AE of fever (defined as ≥38°C or ≥100.4°F) was derived from a daily temperature reading recorded within 14 days after vaccination. Fever was excluded from the overall count as no severity grading was applied for it. The percentages were rounded off to the first decimal place.
Time frame: Within 14 Days of each Vaccination (day of vaccination + 13 days)
Percentage of Participants With Any Unsolicited Adverse Events (AEs) After Each Vaccination
An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a trial vaccine; it does not necessarily have to have a causal relationship with trial vaccine administration.
Time frame: Within 28 days (day of vaccination + 27 days) after each vaccination
Percentage of Participants With Serious Adverse Events (SAEs)
An SAE was defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, leads to a congenital anomaly/birth defect in the offspring of a participant, is an important medical event that may require intervention to prevent any of the above mentioned criteria and/or may expose the participant to danger, even though the event is not immediately life threatening or fatal or does not result in hospitalization. The percentages were rounded off to the first decimal place.
Time frame: From the first vaccination on Day 1 until the end of the trial (Day 270)
Percentage of Participants With Medically Attended Adverse Events (MAAEs)
MAAEs are defined as AEs leading to an unscheduled visit to or by a healthcare professional, including visits to an emergency department, but not fulfilling seriousness criteria. The percentages were rounded off to the first decimal place.
Time frame: From the first vaccination on Day 1 until the end of the trial (Day 270)
Participants took part in the study at 14 investigative sites in the United States from 12 February 2018 to 14 January 2019.
| Milestone | Placebo | TDV Lot 1 | TDV Lot 2 | TDV Lot 3 |
|---|---|---|---|---|
| Started | 132 | 263 | 264 | 264 |
| Received at least 1 dose of the ip | 131 | 263 | 262 | 263 |
| Completed | 113 | 228 | 237 | 234 |
| Not completed | 19 | 35 | 27 | 30 |
| Withdrew: Randomized but not vaccinated | 1 | 0 | 2 | 1 |
| Withdrew: Adverse event | 1 | 1 | 1 | 1 |
| Withdrew: Lost to follow-up | 10 | 19 | 17 | 22 |
| Withdrew: Withdrawal of consent | 4 | 10 | 4 | 5 |
| Withdrew: Death | 1 | 0 | 0 | 0 |
| Withdrew: Reason not specified | 2 | 5 | 3 | 1 |
GMTs of neutralizing antibodies for each of the 4 Dengue Serotypes was measured by microneutralization test 50% \[MNT50\]. The 4 dengue virus serotypes were DENV-1, DENV-2, DENV-3 and DENV-4.
| titer | Placebo | TDV Lot 1 | TDV Lot 2 | TDV Lot 3 |
|---|---|---|---|---|
| DENV-1 | 5.3 (4.7 to 6.1) | 202.9 (155.9 to 264.1) | 293.8 (214.9 to 401.6) | 322.1 (238.1 to 435.9) |
| DENV-2 | 6.3 (4.8 to 8.2) | 3090.3 (2494.8 to 3828.0) | 2386.0 (1913.0 to 2976.1) | 3574.1 (3087.8 to 4137.0) |
| DENV-3 | 5.4 (4.6 to 6.3) | 149.5 (116.6 to 191.6) | 117.3 (92.7 to 148.4) | 122.8 (97.4 to 155.0) |
| DENV-4 | 5.4 (4.7 to 6.2) | 116.3 (93.8 to 144.2) | 187.9 (154.4 to 228.6) | 115.8 (94.0 to 142.5) |
Seropositivity was defined as a reciprocal neutralizing titer ≥ 10. The 4 dengue virus serotypes were DENV-1, DENV-2, DENV-3 and DENV-4.
| percentage of participants | Placebo | TDV Lot 1 | TDV Lot 2 | TDV Lot 3 |
|---|---|---|---|---|
| DENV-1, Day 120 | 1.7 (0.0 to 8.9) | 97.5 (92.9 to 99.5) | 96.9 (92.3 to 99.1) | 99.2 (95.4 to 100.0) |
| DENV-2, Day 120 | 6.7 (1.8 to 16.2) | 99.2 (95.4 to 100.0) | 98.4 (94.5 to 99.8) | 100.0 (96.9 to 100.0) |
| DENV-3, Day 120 | 1.7 (0.0 to 8.9) | 97.5 (92.9 to 99.5) | 94.6 (89.1 to 97.8) | 98.3 (94.0 to 99.8) |
| DENV-4, Day 120 | 1.7 (0.0 to 8.9) | 97.5 (92.9 to 99.5) | 100.0 (97.2 to 100.0) | 97.5 (92.7 to 99.5) |
| DENV-1, Day 270 | 3.4 (0.4 to 11.7) | 97.3 (92.3 to 99.4) | 89.4 (82.6 to 94.3) | 95.8 (90.5 to 98.6) |
| DENV-2, Day 270 | 6.8 (1.9 to 16.5) | 100.0 (96.7 to 100.0) | 97.6 (93.1 to 99.5) | 99.2 (95.4 to 100.0) |
| DENV-3, Day 270 | 0 (0.0 to 6.1) | 95.5 (89.8 to 98.5) | 88.7 (81.8 to 93.7) | 92.5 (86.2 to 96.5) |
| DENV-4, Day 270 | 0 (0.0 to 6.1) | 92.8 (86.3 to 96.8) | 94.3 (88.6 to 97.7) | 91.7 (85.2 to 95.9) |
GMTs of neutralizing antibodies for each of the 4 Dengue Serotypes was measured by microneutralization test 50% \[MNT50\]. The 4 dengue virus serotypes were DENV-1, DENV-2, DENV-3 and DENV-4.
| titer | Placebo | TDV Lot 1 | TDV Lot 2 | TDV Lot 3 |
|---|---|---|---|---|
| DENV-1 | 5.4 (4.9 to 5.9) | 122.5 (93.0 to 161.3) | 136.7 (95.2 to 196.3) | 168.4 (120.8 to 234.8) |
| DENV-2 | 5.8 (5.0 to 6.8) | 1507.2 (1242.3 to 1828.4) | 1097.5 (856.9 to 1405.5) | 1693.3 (1399.9 to 2048.3) |
| DENV-3 | NA (NA to NA) | 88.0 (69.2 to 111.9) | 63.1 (49.9 to 79.7) | 71.6 (57.3 to 89.5) |
| DENV-4 | NA (NA to NA) | 64.1 (49.5 to 83.1) | 77.5 (60.8 to 98.8) | 51.2 (40.0 to 65.5) |
Solicited local AEs (at injection site) were collected by participants using diary cards within 7 days after vaccination and included pain (none, mild: no interference with daily activity, moderate: interference with daily activity with or without treatment and severe: prevents daily activity with or without treatment), redness (erythema) (\<25 mm, mild: \>25 - ≤50 mm, moderate: \>50 - ≤100 mm, severe: \>100 mm) and swelling (edema/induration) (\<25 mm, mild: \>25 - ≤50 mm, moderate: \>50 - ≤100 mm, severe: \>100 mm ). The percentages were rounded off to the first decimal place.
| percentage of participants | Placebo | TDV Lot 1 | TDV Lot 2 | TDV Lot 3 |
|---|---|---|---|---|
| After Vaccination 1, Any Local AE | 17.5 | 51.0 | 48.4 | 50.0 |
| After Vaccination 1, Pain-Any Severity | 16.7 | 45.5 | 40.6 | 41.7 |
| After Vaccination 1, Pain-Mild | 15.0 | 39.9 | 34.8 | 37.7 |
| After Vaccination 1, Pain-Moderate | 1.7 | 5.5 | 5.1 | 4.0 |
| After Vaccination 1, Pain-Severe | 0 | 0 | 0.8 | 0 |
| After Vaccination 1, Erythema-Any Severity | 0.8 | 25.7 | 20.3 | 23.0 |
| After Vaccination 1, Erythema-Mild: 2.5-5(cm) | 0 | 23.7 | 18.4 | 21.8 |
| After Vaccination 1,Erythema-Moderate: >5-<=10(cm) | 0 | 1.2 | 2.0 | 0.8 |
| After Vaccination 1, Erythema-Missing Severity | 0.8 | 0.8 | 0 | 0.4 |
| After Vaccination 1, Swelling-Any Severity | 0.8 | 7.9 | 5.5 | 6.3 |
| After Vaccination 1, Swelling-Mild: 2.5-5(cm) | 0 | 7.1 | 5.1 | 5.6 |
| After Vaccination 1,Swelling-Moderate: >5-<=10(cm) | 0 | 0.4 | 0.4 | 0 |
| After Vaccination 1, Swelling-Missing Severity | 0.8 | 0.4 | 0 | 0.8 |
| After Vaccination 2, Local AE-Any | 13.0 | 37.9 | 42.1 | 37.1 |
| After Vaccination 2, Pain-Any Severity | 13.0 | 32.8 | 34.6 | 30.9 |
| After Vaccination 2, Pain-Mild | 13.0 | 27.6 | 30.0 | 28.4 |
| After Vaccination 2, Pain-Moderate | 0 | 3.9 | 3.8 | 2.5 |
| After Vaccination 2, Pain-Severe | 0 | 1.3 | 0.8 | 0 |
| After Vaccination 2, Erythema-Any Severity | 0 | 19.0 | 18.8 | 14.3 |
| After Vaccination 2,Erythema-Mild: 2.5-5(cm) | 0 | 18.1 | 17.1 | 13.1 |
| After Vaccination 2,Erythema-Moderate: >5-<=10(cm) | 0 | 0.4 | 1.7 | 1.3 |
| After Vaccination 2,Erythema-Missing Severity | 0 | 0.4 | 0 | 0 |
| After Vaccination 2, Swelling-Any Severity | 0 | 6.9 | 4.2 | 4.7 |
| After Vaccination 2,Swelling-Mild: 2.5-5(cm) | 0 | 6.5 | 4.2 | 4.2 |
| After Vaccination 2,Swelling-Moderate: >5-<=10(cm) | 0 | 0 | 0 | 0.4 |
| After Vaccination 2,Swelling-Missing Severity | 0 | 0.4 | 0 | 0 |
Solicited systemic AEs include fever, headache, asthenia, malaise and myalgia that occurred within 14 days after each vaccination. Solicited systemic AEs (headache, asthenia, malaise and myalgia) was graded from 0 to 3 by severity; where 0=None, 1=Mild: No interference with daily activity, 2=Moderate: Interference with daily activity, 3=Severe: Prevents daily activity; A systemic AE of fever (defined as ≥38°C or ≥100.4°F) was derived from a daily temperature reading recorded within 14 days after vaccination. Fever was excluded from the overall count as no severity grading was applied for it. The percentages were rounded off to the first decimal place.
| percentage of participants | Placebo | TDV Lot 1 | TDV Lot 2 | TDV Lot 3 |
|---|---|---|---|---|
| After Vaccination 1, Systemic AEs-Any | 34.7 | 43.3 | 39.5 | 42.9 |
| After Vaccination 1, Headache-Any Severity | 22.5 | 28.9 | 27.0 | 28.6 |
| After Vaccination 1, Headache-Mild | 17.5 | 21.3 | 19.9 | 21.4 |
| After Vaccination 1, Headache-Moderate | 4.2 | 5.9 | 5.5 | 6.0 |
| After Vaccination 1, Headache-Severe | 0.8 | 1.6 | 1.6 | 1.2 |
| After Vaccination 1, Asthenia-Any Severity | 9.2 | 13.1 | 15.2 | 11.9 |
| After Vaccination 1, Asthenia-Mild | 7.5 | 7.9 | 9.4 | 6.3 |
| After Vaccination 1, Asthenia-Moderate | 0.8 | 3.6 | 4.3 | 4.8 |
| After Vaccination 1, Asthenia-Severe | 0.8 | 1.6 | 1.6 | 0.8 |
| After Vaccination 1, Malaise-Any Severity | 12.4 | 15.5 | 14.5 | 15.5 |
| After Vaccination 1, Malaise-Mild | 9.1 | 7.1 | 7.8 | 8.3 |
| After Vaccination 1, Malaise-Moderate | 2.5 | 6.3 | 4.7 | 5.6 |
| After Vaccination 1, Malaise-Severe | 0.8 | 2.0 | 2.0 | 1.6 |
| After Vaccination 1, Myalgia-Any Severity | 15.8 | 26.5 | 25.4 | 22.2 |
| After Vaccination 1, Myalgia-Mild | 13.3 | 19.0 | 16.0 | 14.3 |
| After Vaccination 1, Myalgia-Moderate | 2.5 | 7.1 | 7.8 | 7.5 |
| After Vaccination 1, Myalgia-Severe | 0 | 0.4 | 1.6 | 0.4 |
| After Vaccination 1, Fever-Any Severity | 1.7 | 0.8 | 2.4 | 2.0 |
| After Vaccination 1, Fever-38.0-<38.5 | 0.8 | 0.4 | 0.8 | 1.2 |
| After Vaccination 1, Fever-38.5-<39.0 | 0 | 0.4 | 0.8 | 0.8 |
| After Vaccination 1, Fever-39.0-<39.5 | 0.8 | 0 | 0.4 | 0 |
| After Vaccination 1, Fever-≥41.0 | 0 | 0 | 0.4 | 0 |
| After Vaccination 2, Systemic AEs-Any | 23.5 | 26.7 | 29.2 | 28.0 |
| After Vaccination 2, Headache-Any Severity | 19.1 | 18.1 | 22.5 | 18.6 |
| After Vaccination 2, Headache-Mild | 15.7 | 15.1 | 15.8 | 13.6 |
| After Vaccination 2, Headache-Moderate | 3.5 | 3.0 | 5.4 | 4.2 |
| After Vaccination 2, Headache-Severe | 0 | 0 | 1.3 | 0.8 |
| After Vaccination 2, Asthenia-Any Severity | 8.7 | 9.1 | 8.8 | 6.0 |
| After Vaccination 2, Asthenia-Mild | 7.0 | 6.0 | 6.3 | 3.4 |
| After Vaccination 2, Asthenia-Moderate | 1.7 | 3.0 | 2.1 | 2.1 |
| After Vaccination 2, Asthenia-Severe | 0 | 0 | 0.4 | 0.4 |
| After Vaccination 2, Malaise-Any Severity | 7.8 | 11.6 | 11.3 | 7.7 |
| After Vaccination 2, Malaise-Mild | 5.2 | 7.3 | 7.5 | 4.7 |
| After Vaccination 2, Malaise-Moderate | 2.6 | 4.3 | 3.3 | 2.1 |
| After Vaccination 2, Malaise-Severe | 0 | 0 | 0.4 | 0.9 |
| After Vaccination 2, Myalgia-Any Severity | 7.8 | 16.8 | 14.6 | 14.9 |
| After Vaccination 2, Myalgia-Mild | 5.2 | 12.1 | 10.4 | 11.9 |
| After Vaccination 2, Myalgia-Moderate | 2.6 | 3.9 | 3.3 | 2.6 |
| After Vaccination 2, Myalgia-Severe | 0 | 0.9 | 0.8 | 0.4 |
| After Vaccination 2, Fever-Any Severity | 1.7 | 0.9 | 0.8 | 2.1 |
| After Vaccination 2, Fever-38.0-<38.5 | 1.7 | 0.9 | 0.4 | 0.9 |
| After Vaccination 2, Fever-38.5-<39.0 | 0 | 0 | 0.4 | 0.4 |
| After Vaccination 2, Fever-39.0-<39.5 | 0 | 0 | 0 | 0.4 |
| After Vaccination 2, Fever-39.5-<40.0 | 0 | 0 | 0 | 0.4 |
An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a trial vaccine; it does not necessarily have to have a causal relationship with trial vaccine administration.
| percentage of participants | Placebo | TDV Lot 1 | TDV Lot 2 | TDV Lot 3 |
|---|---|---|---|---|
| After First Vaccination | 13.7 | 18.6 | 18.0 | 16.7 |
| After Second Vaccination | 7.8 | 10.5 | 7.7 | 6.6 |
An SAE was defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, leads to a congenital anomaly/birth defect in the offspring of a participant, is an important medical event that may require intervention to prevent any of the above mentioned criteria and/or may expose the participant to danger, even though the event is not immediately life threatening or fatal or does not result in hospitalization. The percentages were rounded off to the first decimal place.
| percentage of participants | Placebo | TDV Lot 1 | TDV Lot 2 | TDV Lot 3 |
|---|---|---|---|---|
| Percentage of Participants With Serious Adverse Events (SAEs) | 3.1 | 3.8 | 1.1 | 1.1 |
MAAEs are defined as AEs leading to an unscheduled visit to or by a healthcare professional, including visits to an emergency department, but not fulfilling seriousness criteria. The percentages were rounded off to the first decimal place.
| percentage of participants | Placebo | TDV Lot 1 | TDV Lot 2 | TDV Lot 3 |
|---|---|---|---|---|
| Percentage of Participants With Medically Attended Adverse Events (MAAEs) | 13.7 | 17.8 | 12.3 | 11.8 |
Collected over All-cause mortality and Serious adverse events: From the first vaccination on Day 1 until the end of the trial (Day 270); Other adverse events: Up to 28 days (Day of vaccination+27 subsequent days) after each vaccination.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 1/131 (0.8%) | 4/131 (3.1%) | 4/131 (3.1%) |
| TDV Lot 1 | 0/264 (0%) | 10/264 (3.8%) | 16/264 (6.1%) |
| TDV Lot 2 | 0/261 (0%) | 3/261 (1.1%) | 26/261 (10%) |
| TDV Lot 3 | 0/263 (0%) | 3/263 (1.1%) | 23/263 (8.7%) |
| Event | Placebo | TDV Lot 1 | TDV Lot 2 | TDV Lot 3 |
|---|---|---|---|---|
| PneumoniaInfections and infestations | 1/131 | 0/264 | 0/261 | 0/263 |
| SepsisInfections and infestations | 1/131 | 0/264 | 0/261 | 0/263 |
| HypercalcaemiaMetabolism and nutrition disorders | 1/131 | 0/264 | 0/261 | 0/263 |
| Lung squamous cell carcinoma stage IVNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/131 | 0/264 | 0/261 | 0/263 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/131 | 0/264 | 0/261 | 0/263 |
| Intracranial aneurysmNervous system disorders | 1/131 | 0/264 | 0/261 | 0/263 |
| Postmenopausal haemorrhageReproductive system and breast disorders | 1/131 | 0/264 | 0/261 | 0/263 |
| SciaticaNervous system disorders | 0/131 | 2/264 | 0/261 | 0/263 |
| Rhegmatogenous retinal detachmentEye disorders | 0/131 | 0/264 | 1/261 | 0/263 |
| NauseaGastrointestinal disorders | 0/131 | 0/264 | 1/261 | 0/263 |
| Event | Placebo | TDV Lot 1 | TDV Lot 2 | TDV Lot 3 |
|---|---|---|---|---|
| Injection site pruritusGeneral disorders | 0/131 | 8/264 | 15/261 | 3/263 |
| Injection site bruisingGeneral disorders | 1/131 | 5/264 | 10/261 | 12/263 |
| Upper respiratory tract infectionInfections and infestations | 4/131 | 4/264 | 6/261 | 9/263 |
Randomized Set included all randomized participants irrespective of whether a dose of the trial vaccine (TDV or placebo) was received.
| Age, Continuous(years) | Placebo | TDV Lot 1 | TDV Lot 2 | TDV Lot 3 | Total |
|---|---|---|---|---|---|
| Mean | 40.7 ± 11.70 | 40.8 ± 12.54 | 42.0 ± 11.71 | 40.9 ± 12.77 | 41.2 ± 12.25 |
| Sex: Female, Male(Participants) | Placebo | TDV Lot 1 | TDV Lot 2 | TDV Lot 3 | Total |
|---|---|---|---|---|---|
| Female | 69 | 144 | 150 | 134 | 497 |
| Male | 63 | 119 | 114 | 130 | 426 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | TDV Lot 1 | TDV Lot 2 | TDV Lot 3 | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 9 | 16 | 25 | 20 | 70 |
| Not Hispanic or Latino | 120 | 247 | 239 | 244 | 850 |
| Unknown or Not Reported | 3 | 0 | 0 | 0 | 3 |
| Race (NIH/OMB)(Participants) | Placebo | TDV Lot 1 | TDV Lot 2 | TDV Lot 3 | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 2 | 0 | 0 | 2 | 4 |
| Asian | 3 | 2 | 4 | 3 | 12 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 1 | 2 |
| Black or African American | 23 | 55 | 56 | 44 | 178 |
| White | 104 | 200 | 202 | 208 | 714 |
| More than one race | 0 | 5 | 2 | 6 | 13 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Height(cm) | Placebo | TDV Lot 1 | TDV Lot 2 | TDV Lot 3 | Total |
|---|---|---|---|---|---|
| Mean | 171.7 ± 10.67 | 171.0 ± 9.68 | 171.6 ± 10.11 | 171.8 ± 9.86 | 171.5 ± 9.99 |
| Weight(kg) | Placebo | TDV Lot 1 | TDV Lot 2 | TDV Lot 3 | Total |
|---|---|---|---|---|---|
| Mean | 82.37 ± 15.275 | 79.63 ± 15.203 | 81.31 ± 16.543 | 82.35 ± 15.928 | 81.28 ± 15.827 |
| Body Mass Index (BMI)(kg/m^2) | Placebo | TDV Lot 1 | TDV Lot 2 | TDV Lot 3 | Total |
|---|---|---|---|---|---|
| Mean | 27.84 ± 3.825 | 27.17 ± 4.270 | 27.50 ± 4.464 | 27.84 ± 4.408 | 27.55 ± 4.309 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Feb 2018 to primary completion in Aug 2018, 5 months.
Results were first posted in Oct 2020, 2 years 2 months after primary completion. A results delay was requested in Jul 2019.
Of 21 phase 3 interventional studies under Dengue, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 30. This study's 5 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.